The Loulou Foundation, a private, non-profit UK foundation dedicated to advancing research into the understanding and development of therapeutics for CDKL5 deficiency disorder, has joined IRDiRC as new funding agency. Next to funding research, the Loulou Foundation places a high priority on partnering with the biopharma industry.
Recursion Pharmaceuticals, Inc, is a US-based company, that has set themselves the challenging goal of discovering 100 rare diseases treatments for rare diseases in the next 7 years. This goal is perfectly aligned with IRDiRCs objectives for therapeutic development. Christoper Gibson, CEO and Co-Founder of Recusion, recently presented at the 3rd IRDiRC Conference, in which he outlined Recursion’s pipeline for drug development.